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iMAIL
Right Ventricular Adaptation Assessed
Using Cardiac Magnetic Resonance
Predicts Survival in Pulmonary Arterial
Hypertension
Pulmonary arterial hypertension (PAH) is a rare but
life-limiting condition. Assessments of disease
severity and prognosis are essential in the selection of
treatment options and the timing of lung trans-
plantation (1). Right ventricular (RV) volume and
mass parameters measured using cardiac magnetic
resonance have been suggested to be prognostic in
PAH (1–3).
This study aimed to determine the prognosis of
patients with PAH based on patterns of RV adaption
in PAH using RV volume and mass. Ethical approval
by the North Sheffield ethics committee and
review board approval was obtained (reference c06/
Q2308/8).
Consecutive patients who underwent cardiac
magnetic resonance and were diagnosed with PAH
from the ASPIRE (Assessing the Spectrum of Pulmo-
nary Hypertension Identified at a Referral Centre)
Registry between May 12, 2009 to February 1, 2015
were included. The patients were followed up until
census or death. RV end-systolic volume was
measured on short-axis cine images, corrected for
body surface area, adjusted for sex and age, and
presented as: RV end-systolic volume index per-
centage predicted (RVESVI%pred) (4). Ventricular
mass index (VMI) was calculated as RV end-
diastolic mass divided by left ventricular end-
diastolic mass. Univariate Cox regression analysis
was used to assess the prognostic value of RVESVI%
pred and VMI.
The patients were divided into 4 different volume/
mass groups using a RVESVI%pred threshold of 227%
(1) and a median value of VMI because there was no
known well-defined PAH prognostic threshold for
VMI. The groups were as follows: VollowMasslow (low
RVESVI%pred and low VMI), VollowMasshigh (low
RVESVI%pred and high VMI), VolhighMasslow (high
RVESVI%pred and low VMI), and VolhighMasshigh (high
RVESVI%pred and high VMI). Kaplan-Meier plots, Cox
regression analysis, and one-way analysis of
variance were used to compare the prognoses and
variables of different groups. Multivariate Cox
regression analysis was used to identify prognostic
indicators that were independent of volume/mass
group. Subgroup analyses were performed in
incident patients.
A total of 564 patients with PAH were identified;
250 (44%) died at follow-up (mean 5.0  2.6 years).
RVESVI%pred (scaled hazard ratio [HR]: 1.323; 95%
confidence interval [CI]: 1.183 to 1.480; p < 0.001) and
VMI (scaled HR: 0.864; 95% CI: 0.757 to 0.985;
p ¼ 0.029) had prognostic value.
Complete RV mass and volume data were available
for 550 patients who were included in the group
comparison study. We excluded 14 patients (2.5%)
due to missing data. The VMI threshold was 0.53
(median). The numbers of patients in each group
were as follows: 189 VollowMasslow, 84 VollowMasshigh,
85 VolhighMasslow, and 192 VolhighMasshigh. There
were 69% of patients who had concordant remodeling
(VollowMasslow and VolhighMasshigh) and 31% had
discordant remodeling (VollowMasshigh and Volhigh-
Masslow). VollowMasslow (HR: 0.390; 95% CI: 0.275 to
0.554; p < 0.001), VollowMasshigh (HR: 0.260; 95% CI:
0.164 to 0.411; p < 0.001) and VolhighMasshigh (HR:
0.524; 95% CI: 0.373 to 0.734; p < 0.001) had lower
mortality than VolhighMasslow. One-way analysis of
variance test showed that VolhighMasslow patients had
the highest mean age (67  13 years). At multivariate
Cox regression analysis, VolhighMasslow group
(p ¼ 0.001) was independent of age, sex, World
Health Organization functional class, and pulmonary
vascular resistance. For the subgroup analysis of
incident treatment-naive patients (n ¼ 383), the
threshold for VMI was 0.55. Figure 1 illustrates the
survival of patients by volume/mass group in the
full and incident cohort.
Regarding limitations, the study cohort consisted
of patients referred to a single tertiary center and
would benefit from prospective validation. Assess-
ment of longitudinal changes in volume/mass classi-
fication would be of great interest. The study used the
previous diagnostic threshold of pulmonary hyper-
tension (mPAP $25 mm Hg and pulmonary vascular
resistance >3 WU).
The study has identified that VolhighMasslow is a
maladaptive cardiac phenotype in PAH and may be
important to recognize to guide optimal counselling
and therapy. Because individuals with VolhighMas-
slow were older than other groups, one factor may
be that, in older patients with significant pulmonary
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vascular disease, the RV maladapts with insufficient
adaptive hypertrophy to maintain RV function.
VolhighMasslow remained prognostic following
adjustment for age, suggesting that age does not
fully explain the poor outcome, and, at all ages,
VolhighMasslow should alert the physician of high
risk of adverse outcome. In contrast, VollowMasslow
patients had less RV remodeling and maintained
better RV function. VollowMasshigh and VolhighMas-
shigh had better prognoses potentially through
adaptive concentric hypertrophy that increases the
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Log rank test Chi square
15.22, p < 0.0003
Log rank test Chi square
29.24, p < 0.0003
Log rank test Chi square
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Log rank test Chi square
19.91, p < 0.0003
Log rank test Chi square
23.97, p < 0.0003
Log rank test Chi square









Kaplan-Meier graphs of the full cohort (left) and the incident treatment-naïve group (right). Number at risk each year was presented below each plot. Log-rank test
result comparing each group with VolhighMasslow was shown, with Bonferroni p value. CMR ¼ cardiac magnetic resonance.
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